REDD1 contribue au dialogue entre le métabolisme énergétique et la masse musculaire.REDD1 est une protéine ubiquitaire et conservée qui est exprimée en réponse à de nombreux stress et pathologies associés à une atrophie du muscle squelettique, un paramètre corrélé à la mortalité des patients. REDD1 est connue pour inhiber la voie Akt/mTORC1 qui contrôle la synthèse des protéines (composants majoritaires du muscle), mais également d'autres macromolécules tels les ribosomes, les nucléotides ou le glycogène. Nos travaux montrent, grâce à un modèle murin, que REDD1 est capable d'une part d'inhiber la synthèse protéique ce qui conduit à l'atrophie du muscle, et d'autre part de réduire le stockage du glycogène musculaire. Cependant, sa délétion est responsable d'une augmentation du métabolisme basal, d'une réduction de la capacité d'exercice et d'une aggravation de l'atrophie musculaire en situation d'hypoxie. Ces altérations du métabolisme ne sont pas liées à un dysfonctionnement mitochondrial, mais associées à une moindre inhibition de la signalisation d'Akt et/ou mTORC1, tous deux responsables de l'activation de processus anaboliques couteux en énergie. Pris ensembles, ces résultats suggèrent que REDD1 agit comme modérateur de la dépense en ATP dans des situations de stress énergétique. / REDD1 contributes to the crosstalk between energetic metabolism and skeletal muscle mass. REDD1 is a ubiquitous and conserved protein, which is expressed in response to numerous stresses and pathologies responsible of muscle atrophy, a parameter correlated with patient mortality. REDD1 is known to inhibit Akt/mTORC1 pathway which controls synthesis of proteins (the major component of muscle) and other macromolecules such as ribosome, nucleotide or glycogen. Our work shows on a mice model that REDD1 inhibits protein synthesis, leading to skeletal muscle atrophy, and reduces muscle glycogen storage. However, REDD1 deletion is responsible of an increase in basal metabolism, a reduction of exercise capacity and an exacerbation of hypoxia-induced skeletal muscle atrophy. These metabolic alterations are not associated with a mitochondrial dysfunction but rather with an hyper activation of the Akt/mTORC1 pathway which is responsible for the stimulation of energy demanding processes. Altogether, these results strongly suggest that REDD1 acts for moderating ATP demand in energetic stress conditions

A disfunção cardíaca, decorrente de um prejuízo na contratilidade miocárdica, tem sido reconhecida como um fator importante que contribui para as altas taxas de mortalidade na sepse. Outro fato importante aponta para o envolvimento das calpaínas na inibição da via de sinalização PI3K/mTOR levando a uma diminuição potencial das taxas globais de síntese proteica através da redução da maquinaria de tradução disponível, o que reforça o envolvimento destes elementos na progressão da disfunção cardíaca na sepse. Metodologia: Foram utilizados camundongos da linhagem C57/BL6 para indução de sepse através da técnica de ligadura e perfuração do ceco separados em quatro grupos: controle com e sem tratamento e sepse moderada com e sem tratamento, o tratamento foi realizado 2 horas antes da cirurgia com inibidor da via mTOR, rapamicina. Foi realizada análise histopatológica em metacrilato e coloração picrosirius para colágeno, western blotting para quantificação da expressão proteica e real-time PCR para quantificação da expressão gênica, por fim realizamos análise funcional através da ecocardiografia. Resultados: Foi encontrado aumento das lesões teciduais e depósito de colágeno no grupo séptico tratado com rapamicina. A análise por western blotting e real-time PCR demonstrou redução das proteínas envolvidas na via mTOR nos grupos sépticos com e sem tratamento com ênfase no grupo tratado e por fim a avaliação funcional mostrou redução dos parâmetros débito cardíaco e fração de ejeção nos grupos sépticos com e sem tratamento. Conclusão: Nossos resultados demonstram que a via mTOR é de extrema importância na estrutura e função cardíacas, visto que sua inibição ocasionou o aumento de lesões e deposição de colágeno juntamente com alterações funcionais, podendo se transformar em um possível alvo terapêutico para futuras pesquisas clínicas em animais e humanos. / Cardiac dysfunction, due to impairment in myocardial contractility, has been recognized as an important factor contributing to the high mortality rates in sepsis. Another important fact is the involvement of the calpain in the inhibition of the PI3K / mTOR signaling pathway leading to a potential decrease in the overall rates of protein synthesis through the reduction of available translation machinery, which reinforces the involvement of these elements in the progression of cardiac dysfunction in sepsis. Methods: C57 / BL6 mice were used for induction of sepsis through the technique of ligation and perforation of the cecum separated into four groups: control with and without treatment and moderate sepsis with and without treatment, treatment was performed 2 hours before surgery with mTOR pathway inhibitor, rapamycin. Histopathological analysis was performed on methacrylate and picrosirius staining for collagen, western blotting for quantification of protein expression and real-time PCR for quantification of gene expression. Finally we performed functional analysis through echocardiography. Results: Increased tissue lesions and collagen deposition were found in the septic group treated with rapamycin. Western blotting and real-time PCR analysis showed reduction of the proteins involved in the mTOR pathway in the septic groups with and without treatment with emphasis in the treated group and finally the functional evaluation showed a reduction of the parameters cardiac output and ejection fraction in the septic groups with and without treatment. Conclusion: Our results demonstrate that the mTOR pathway is extremely important in cardiac structure and function, since its inhibition has resulted in increased lesions and collagen deposition along with functional alterations, and may become a possible therapeutic target for future clinical research in animals and humans.

La survie des cellules cancéreuses dépend d’une activité énergétique et biosynthétique accrue et la glutamine participe à de nombreux processus nécessaires à cette adaptation métabolique. Dans les leucémies aiguës myéloïdes (LAM), la croissance et la prolifération sont favorisées par l’activation anormale de plusieurs voies de signalisation, et notamment par la voie mTORC1. Les acides aminés essentiels, et en particulier la leucine, sont indispensables à l’activation de mTORC1. La glutamine est captée par la cellule via le transporteur SLC1A5 et permet ensuite l’entrée de la leucine via le transporteur bidirectionnel SLC7A5. La concentration en glutamine est donc une étape limitante dans l’activation de mTORC1 par la leucine. Nous avons étudié les effets de la privation en glutamine dans les LAM à l’aide de différents outils (milieu sans glutamine, shARN inhibant l’expression du transporteur de la glutamine SLC1A5 et la drogue L-asparaginase, qui a une activité de glutaminase extracellulaire), et observé une inhibition de mTORC1 et de la synthèse protéique. L’inhibition du transporteur SLC1A5 inhibe la pousse tumorale dans un modèle de xénotransplantation. La L-asparaginase inhibe mTORC1 et induit une apoptose de façon proportionnelle à son activité glutaminase et complètement indépendante de la concentration en asparagine. La privation en glutamine induit l’expression de la glutamine synthase et l’autophagie, et ces deux processus peuvent être des mécanismes de résistance intrinsèques ou acquis dans certaines lignées leucémiques. L’apoptose induite par la privation en glutamine n’est cependant pas liée à l’inhibition de mTORC1, puisqu’elle n’est pas diminuée par l’utilisation d’un mutant de mTOR non inhibé par la privation en glutamine. Nous nous sommes donc intéressés à une autre voie dépendante de la glutamine dans de nombreux cancers, la phosphorylation oxydative. L’étape initiale du catabolisme intracellulaire de la glutamine est la conversion de la glutamine en glutamate par des enzymes appelées glutaminases. Différentes isoformes des glutaminases existent qui sont codées chez l’homme par les gènes GLS1 et GLS2. Le glutamate est ensuite transformé en α-cétoglutarate, intermédiaire du cycle TCA. Dans les lignées de LAM, la privation en glutamine inhibe la phosphorylation oxydative mitochondriale. Nous avons observé que la protéine glutaminase C (GAC), une des isoformes de GLS1, est constamment exprimée dans les LAM mais aussi dans les progéniteurs hématopoïétiques CD34+ normaux. L’inhibition d’expression de la GLS1 par des shARN inductibles ou bien par le composé CB-839 réduit la phosphorylation oxydative, conduisant à une inhibition de prolifération et à une induction d’apoptose des cellules leucémiques. L’invalidation génétique de la GLS1 inhibe la formation de tumeur et améliore la survie des souris dans un modèle de xénotransplantation. A l’inverse, le ciblage de la GLS1 n’a pas d’effets cytotoxiques ni cytostatiques sur les progéniteurs hématopoïétiques normaux. Ces effets anti-leucémiques sont inhibés par l’adjonction d’α-cétoglutarate, et ceux induit par le CB-839 sont abrogés lorsqu’est exprimé de façon ectopique un mutant GACK320A hyperactif, attestant du rôle essentiel du maintien d’un cycle TCA actif dans les cellules de LAM. Enfin, nous montrons que l’inhibition de la glutaminolyse active la voie d’apoptose mitochondriale intrinsèque et agit en synergie avec l’inhibition spécifique de BCL-2 par l’ABT-199. Ces résultats démontrent que le ciblage spécifique de la glutaminolyse est une autre façon d’exploiter l’addiction à la glutamine des cellules leucémiques de LAM et que le maintien d’un cycle TCA actif est essentiel à la survie de ces cellules. / Cancer cells survival is dependent on high energetic and biosynthetic activity, and glutamine is involved in many metabolic processes necessary for this adaptation. In acute myeloid leukemia (AML), growth and proliferation are promoted by activation of several signaling pathways, including mTORC1. Essential amino acids, in particular leucine, are required for mTORC1 activation. Glutamine enters into the cell via the SLC1A5 transporter and then allows the input of leucine via the bidirectional SLC7A5 transporter. Therefore, the intracellular glutamine concentration is a limiting step in the activation of mTORC1 by leucine. We studied the effects of glutamine deprivation in AML using different tools (medium without glutamine, shRNA against the SLC1A5 glutamine transporter and the drug L-asparaginase, which has an extracellular glutaminase activity) and observed mTORC1 and protein synthesis inhibition. SLC1A5 transporter knockdown inhibits tumor growth in a xenotransplantation model. L-asparaginase inhibits mTORC1 and induces apoptosis in proportion to its glutaminase activity and independently of asparagine concentration. Glutamine privation induces the expression of glutamine synthase and autophagy, and these two processes are involved in the resistance to glutamine privation in some leukemic cell lines. However, apoptosis induced by glutamine privation is not related to the inhibition of mTORC1, since it is not modified in the presence of a constitutively active mutant of mTOR. We next focused on the oxidative phosphorylation, another glutamine dependent pathway in many cancers. The initial step of the intracellular catabolism of glutamine is the conversion of glutamine to glutamate by enzymes called glutaminases. Different glutaminases isoforms exist that are encoded by the GLS1 and GLS2 genes. Glutamate is then converted to α-ketoglutarate, an essential TCA cycle intermediate. In AML cell lines, we observed that glutamine privation inhibits mitochondrial oxidative phosphorylation. The protein glutaminase C (GAC), an isoform of GLS1, is constantly expressed in AML but also in normal CD34 + hematopoietic progenitors. The knockdown of GLS1 by inducible shRNA or by the CB-839 compound reduced oxidative phosphorylation, leading to proliferation inhibition and apoptosis induction in leukemia cells. Genetic invalidation of GLS1 inhibits tumor formation and improves survival of mice in a xenograft model. Conversely, the targeting of GLS1 has no cytotoxic or cytostatic effects on normal hematopoietic progenitors. These anti-leukemic effects are inhibited by the addition of α-ketoglutarate, and those induced by the CB-839 are suppressed in the presence of an ectopically expressed GACK320A hyperactive mutant, confirming the essential role of maintaining an active TCA cycle in AML cells. Finally, we showed that glutaminolysis inhibition induces the intrinsic mitochondrial pathway of apoptosis and acts synergistically with the specific inhibition of BCL-2 by ABT-199. These results demonstrate that specific targeting of glutaminolysis is another way to exploit glutamine addiction in AML and that an active TCA cycle in essential for AML cell survival.

A disfunção cardíaca, decorrente de um prejuízo na contratilidade miocárdica, tem sido reconhecida como um fator importante que contribui para as altas taxas de mortalidade na sepse. Outro fato importante aponta para o envolvimento das calpaínas na inibição da via de sinalização PI3K/mTOR levando a uma diminuição potencial das taxas globais de síntese proteica através da redução da maquinaria de tradução disponível, o que reforça o envolvimento destes elementos na progressão da disfunção cardíaca na sepse. Metodologia: Foram utilizados camundongos da linhagem C57/BL6 para indução de sepse através da técnica de ligadura e perfuração do ceco separados em quatro grupos: controle com e sem tratamento e sepse moderada com e sem tratamento, o tratamento foi realizado 2 horas antes da cirurgia com inibidor da via mTOR, rapamicina. Foi realizada análise histopatológica em metacrilato e coloração picrosirius para colágeno, western blotting para quantificação da expressão proteica e real-time PCR para quantificação da expressão gênica, por fim realizamos análise funcional através da ecocardiografia. Resultados: Foi encontrado aumento das lesões teciduais e depósito de colágeno no grupo séptico tratado com rapamicina. A análise por western blotting e real-time PCR demonstrou redução das proteínas envolvidas na via mTOR nos grupos sépticos com e sem tratamento com ênfase no grupo tratado e por fim a avaliação funcional mostrou redução dos parâmetros débito cardíaco e fração de ejeção nos grupos sépticos com e sem tratamento. Conclusão: Nossos resultados demonstram que a via mTOR é de extrema importância na estrutura e função cardíacas, visto que sua inibição ocasionou o aumento de lesões e deposição de colágeno juntamente com alterações funcionais, podendo se transformar em um possível alvo terapêutico para futuras pesquisas clínicas em animais e humanos. / Cardiac dysfunction, due to impairment in myocardial contractility, has been recognized as an important factor contributing to the high mortality rates in sepsis. Another important fact is the involvement of the calpain in the inhibition of the PI3K / mTOR signaling pathway leading to a potential decrease in the overall rates of protein synthesis through the reduction of available translation machinery, which reinforces the involvement of these elements in the progression of cardiac dysfunction in sepsis. Methods: C57 / BL6 mice were used for induction of sepsis through the technique of ligation and perforation of the cecum separated into four groups: control with and without treatment and moderate sepsis with and without treatment, treatment was performed 2 hours before surgery with mTOR pathway inhibitor, rapamycin. Histopathological analysis was performed on methacrylate and picrosirius staining for collagen, western blotting for quantification of protein expression and real-time PCR for quantification of gene expression. Finally we performed functional analysis through echocardiography. Results: Increased tissue lesions and collagen deposition were found in the septic group treated with rapamycin. Western blotting and real-time PCR analysis showed reduction of the proteins involved in the mTOR pathway in the septic groups with and without treatment with emphasis in the treated group and finally the functional evaluation showed a reduction of the parameters cardiac output and ejection fraction in the septic groups with and without treatment. Conclusion: Our results demonstrate that the mTOR pathway is extremely important in cardiac structure and function, since its inhibition has resulted in increased lesions and collagen deposition along with functional alterations, and may become a possible therapeutic target for future clinical research in animals and humans.

Dans le but de maintenir leur métabolisme et leur prolifération exacerbée, les tumeurs sont dépendantes d’un apport accru en acides aminés. Afin d'optimiser cet apport, les tumeurs surexpriment certains transporteurs clés tels que l'hétérodimère multifonctionnel CD98/LAT1. CD98 (SLC3A2) agit comme co-récepteur des intégrines β et amplifie leur signalisation régulant ainsi la migration et l'adhésion cellulaire. La protéine LAT1 (SLC7A5) est quant à elle responsable du transport des acides aminés (AA) essentiels. Des études antérieures ont suggéré que la fonction CD98/intégrines du complexe est essentielle à la croissance tumorale, alors que LAT1 aurait un rôle mineur dans ce contexte. Cependant, les besoins nutritifs accrus des cellules tumorales nous ont conduit à émettre l’hypothèse contraire selon laquelle l’avantage prolifératif donné par ce complexe serait en réalité supporté par l’activité du transporteur LAT1 et non pas par l’interaction CD98/intégrine. Dans ce contexte, j’ai montré que l’invalidation génétique ou pharmacologique de LAT1 dans différentes lignées tumorales entraine une suppression totale du transport de la leucine, sodium-indépendant. Ceci entrainant une perte d’homéostasie des AA avec l’activation de la voie de stress GCN2, l’inhibition de mTORC1 et la suppression de la croissance tumorale. De plus, l’invalidation génétique de CD98 ne s’est traduite par aucun phénotype visible. Cependant, la suppression de l'activité résiduelle de LAT1 de ces cellules est suffisante pour abolir leur potentiel tumoral. Ainsi, mes résultats démontrent le rôle clé de LAT1 dans la croissance tumorale en faisant ainsi une cible thérapeutique prometteuse. / Tumours rely on external amino acids (AA) uptake to maintain their exacerbated metabolism and proliferation. To optimize AA uptake, tumors overexpress key carriers such as the multifunctional CD98/LAT 1 heterodimer. CD98 (SLC3A2) acts as a co-receptor of β integrins and enhances signaling that promotes cellular migration and invasion. LAT1 (SLC7A5) is responsible for the transport of essential AA. Previous studies have suggested that the CD98/integrin axis of the complex is essential for tumour growth, while LAT1 activity is dispensible. However, the increased nutritional requirements of tumor cells led us to hypothesize that the proliferative advantage given by this complex is in fact supported by the AA transporter activity of LAT1 and not by the CD98/integrin activity. In this context, I have shown that genetic or pharmacological invalidation of LAT1 in various tumor cell lines leads to a complete removal of the sodium-independent leucine transport. This leads to a loss of AA homeostasis with activation of the GCN2 stress pathway, inhibition of mTORC1 and supression of tumour growth. In addition, genetic invalidation of CD98 did not result in any detectable phenotype. However, inhibition of the residual activity of LAT1 in CD98 knockout cells is sufficient to abolish their tumorigenicity. Thus, my results clearly demonstrate the fundamental role of LAT1 in tumour growth and advocate the pharmacology development of LAT1 transporter inhibitors as very promising anticancer agents.

L’hypothalamus est une structure cérébrale ayant un rôle clé dans la régulation de la prise alimentaire. Parmi les différentes populations neuronales qui le composent, les neurones produisant la pro-opiomélanocortine (POMC) sont classiquement connus pour diminuer la prise alimentaire et le poids corporel via la libération de neuropeptides produits par le clivage de POMC. Notre étude, grâce à l’utilisation d’approches génétiques, pharmacologiques, électrophysiologiques et moléculaires, remet en question les notions classiques sur la fonction des neurones à POMC dans la balance énergétique, en démontrant qu’il existe deux sous-populations fonctionnellement distinctes de neurones à POMC, qui augmentent ou diminuent la prise alimentaire en fonction du neurotransmetteur qu’elles libèrent, l’acide γ-aminobutyrique (GABA) ou le glutamate. Une troisième population capable de produire aussi bien du GABA que du glutamate a également été identifiée. La régulation des neurones à POMC GABAergiques et glutamatergiques dépend de la voie de la cible de la rapamycine chez les mammifères (mTORC1), qui fonctionne comme un détecteur d’énergie cellulaire, et du système endocannabinoïde (ECS), qui régule la libération de neurotransmetteurs. De plus, nous avons également démontré, via l’utilisation de souris mutantes conditionnelles, l’importance de la protéine p62 ou séquestrome 1 (p62/SQSTM1), qui régule l’activité de mTORC1 et l’autophagie, dans les neurones à POMC dans la régulation de l’homéostasie énergétique. Nos données offrent un nouvel aperçu sur les mécanismes moléculaires impliqués dans la régulation de la balance énergétique. / The hypothalamus is a brain structure with a key role in the regulation of food intake. Among the different neuronal populations of which it is composed, pro-opiomelanocortin (POMC) neurons are classically known to decrease food intake and body weight through the release of neuropeptides produced by the cleavage of POMC. Our study, through the use of genetic, pharmacological, electrophysiological and molecular approaches, challenges conventional notions about POMC neuron function in energy balance by showing that there are two functionally distinct POMC neuronal sub-populations, which increase or decrease food intake depending on which neurotransmitter they release, γ-aminobutyric acid (GABA) or glutamate. A third population capable of producing both GABA and glutamate has also been identified. The regulation of POMC GABAergic and glutamatergic neurons depends on the mechanistic target of rapamycin complex 1 (mTORC1) pathway, which functions as a cellular energy sensor, and the endocannabinoid system (ECS), which regulates neurotransmitters release. In addition, we have also demonstrated through the use of a conditional knockout mice, the importance of the protein p62 or sequestrome 1 (p62/SQSTM1), which regulates mTORC1 activity and autophagy, in POMC neurons for the regulation of energy homeostasis. Our data provide new insights on the molecular mechanisms involved in the regulation of energy balance.

Au-delà des symptômes moteurs, la maladie de Parkinson (MP) est également caractérisée par une myriade de symptômes neuropsychiatriques allant de l’apathie et la dépression aux troubles du contrôle des impulsions (TCI). Les TCI représentent un groupe d’addictions comportementales incluant le jeu pathologique, l’hypersexualité et les achats faits de manière compulsive. Observés chez 10 à 14 % des patients parkinsoniens sous traitement dopaminergique, ils affectent fortement leur qualité de vie. L’impulsivité cognitive reflétant notamment l’incapacité à tolérer les délais de renforcements, est au cœur des TCI. En effet, différentes études suggèrent que cette impulsivité serait exacerbée dans la MP et sous traitements dopaminergiques. Cependant, les mécanismes sous-tendant les TCI dans la MP demeurent méconnus, et la contribution respective de la lésion, du traitement dopaminergique, et de certains facteurs de vulnérabilité reste à déterminer. De plus, l’impulsivité d’attente, une autre forme de déficit d’inhibition qui peut conduire au développement de comportements compulsifs, a été peu étudiée dans le cadre des TCI.L’objectif de ce projet de thèse a été d’évaluer l’influence d’une dénervation dopaminergique de la voie nigrostriée, avec ou sans adjonction d’agoniste dopaminergique, sur le développement d’impulsivité. Pour cela, nous avons utilisé un modèle lésionnel des troubles non-moteurs de la MP. Ces rats ont reçu une injection bilatérale de neurotoxine 6-OHDA dans la SNc, afin d’induire une dénervation sélective, bilatérale et partielle du striatum dorsal. Ils ont ensuite été traités avec du pramipexole, un agoniste des récepteurs D2/3, connu pour favoriser le développement de TCI chez les patients parkinsoniens. Les tâches d’intolérance au délai et de réaction en série à 5 choix (5-CSRTT) ont été utilisées pour évaluer respectivement l’impulsivité cognitive et l’impulsivité d’attente. Dans le premier paradigme, les rats doivent appuyer sur un levier pour choisir entre une petite récompense immédiate, ou une plus grosse récompense, avec un un délai. Dans le second paradigme, ils doivent inhiber l’émission d’une réponse motrice jusqu’à l’apparition d’un stimulus lumineux. Le traitement chronique au pramipexole augmente considérablement les choix impulsifs effectués dans la tâche d’intolérance au délai, mais seulement chez les rats non lésés. En effet, la lésion dopaminergique seule ou avec le traitement ne favorise pas les comportements impulsifs. Dans la tâche de 5-CSRTT, le pramipexole semble également promouvoir l’émission de réponses prématurées (effet pro-impulsif), lorsque l’intervalle inter-essais est constant. Cependant, lorsque cet intervalle augmente, le pramipexole provoque à l’inverse une diminution des réponses prématurées (effet anti-impulsif). Cette modulation d’impulsivité étant seulement observée chez les rats hautement impulsifs, ceci suggère qu’un endophénotype impulsif puisse être un facteur de vulnérabilité à l’effet iatrogène du pramipexole.A l’échelle neuronale, ce traitement favorise la surexpression des ARNm codants pour les récepteurs dopaminergiques D2 dans le striatum et y modifie la connectivité glutamatergique telle qu’observée en microscopie électronique. De plus, nous avons observé une suractivation de la voie mTORC1 dans le noyau accumbens, comme déjà constaté dans les processus addictifs. Afin d’apporter un lien causal à cette étude, nous avons bloqué l’activité de la voie mTORC1 par un inhibiteur spécifique, la rapamycine, chez des rats traités au pramipexole. Etonnamment, cette combinaison accentue fortement l’intolérance au délai, alors que la rapamycine seule ne provoque aucun effet notable. Ceci pourrait s’expliquer par une cinétique d’activation et d’inhibition complexe de cette voie. L’ensemble de ces résultats suggère que l’impulsivité observée dans la MP serait causée par une action iatrogène du pramipexole via une activation anormale de la voie mTORC1 dans le noyau accumbens. / Beyond motor symptoms, Parkinson’s disease (PD) is also characterized by a plethora of neuropsychiatric deficits, ranging from apathy and depression to Impulse control disorders (ICDs). ICDs represent a complex group of behavioral addictions including gambling disorders, hypersexuality and compulsive shopping, displayed by 10 to 14% of PD patients under dopamine replacement therapies, whose quality of life is greatly diminished. Importantly, cognitive impulsivity reflecting in particular, an inability to tolerate delays to reinforcements, appears as a core symptom of ICDs. Indeed, recent evidence suggested that this kind of impulsivity would be exacerbated in PD and under treatment by dopaminergic D2/3 receptor agonists. However, the mechanisms underlying ICDs in PD remain unknown and the respective contribution of dopamine lesion and treatment, combined with factors of vulnerability, remain to be determined. Moreover, waiting impulsivity, another form of behavioral inhibition which may lead to compulsive behaviors, has been poorly investigated in the framework of ICDs.In this thesis project, using a lesional rodent model of non-motor symptoms of PD, we addressed the question of whether denervation of the dopaminergic nigrostriatal system would promote the development of impulsivity when combined with dopamine agonist treatments. Rats were bilaterally injected in the SNc with the neurotoxin 6-OHDA to induce selective and partial denervation of the dorsal striatum. We then treated them with the dopamine D2/3 receptor agonist, pramipexole, a medication known to favor the development of ICDs in PD patients. Two different tasks were used to measure cognitive and motor impulsivity: the delay discounting task (DDT) and the 5-choice serial reaction time task (5-CSRTT) respectively. In the former, rats have to press a lever and choose between a smaller, but immediate reward and a larger, but delayed reward. For the latter, they have to wait for a stimulus light to come on. In the DDT, chronic administration of pramipexole treatment only increased impulsive choices in non-lesioned rats. Indeed, the dopaminergic lesion by itself, or in adjunction with the treatment, did not increase impulsivity. In the 5-CSRTT, pramipexole progressively increased premature responses, reflecting a pro-impulsive effect when the inter-trial interval is constant. However, when the interval was increased, pramipexole reduced the premature responses, exhibiting an anti-impulsive effect. Interestingly, this modulation of motor impulsivity was only observed in rats with a high level of impulsivity, suggesting that an impulsive endophenotype might be an important factor of vulnerability to the iatrogenic effects of pramipexole.The effect of this treatment was then investigated at a cellular level. It promotes overexpression of the dopamine D2 receptor mRNA within the striatum, and seems to alter glutamatergic synaptic connectivity suggested by electron microscopy. Moreover, we showed that the mammalian target of rapamycin complex 1 (mTORC1) pathway is lastingly over-activated in the nucleus accumbens, as already observed in drug addictions. In an attempt to make a causal link between this pathway and the behavioral changes, we treated rats with pramipexole and rapamycine, a specific inhibitor of this pathway. Surprisingly, this combination accentuated impulsivity even more, whereas rapamycine by itself did not promote impulsivity. This effect may be explained by the complexity of the kinetics of activation and inhibition of mTORC1 pathway.Taken together, these results suggest that impulsivity in PD may be triggered by an iatrogenic effect of the dopaminergic pramipexole treatment through an abnormal activation of the mTORC1 pathway within the nucleus accumbens.

Skeletal muscle adapts differently to specific modes of exercise, where resistance training results in muscle growth and endurance training induces mitochondrial biogenesis. These are results of molecular events that occur after each exercise session, increasing the expression of specific genes and the rate of both synthesis and breakdown of protein. The rate of protein synthesis is controlled by the mTORC1 signaling pathway, which is potently stimulated by resistance exercise and amino acid, and their combined effect is needed for muscle growth. The essential amino acids (EAA) are responsible for the stimulation of protein synthesis and here leucine has been attributed specific attention, but its particular role among the EAA, and the involvement of the other branched-chain amino acids (BCAA) is unclear. Endurance exercise activates the protein AMPK which, in animal models, has been shown to inhibit mTORC1 signaling and protein synthesis.  Suggesting that concurrent endurance and resistance exercise could restrain muscle growth, but it is unknown if this mechanism is relevant in exercising human muscle. Little is known about the regulation of protein breakdown and although much attention has been given the proteins MuRF-1 and MAFbx which target proteins for degradation, their role requires further investigation. The aim of thesis was to address the mentioned uncertainties by examining how different modes of exercise and amino acids affect mTORC1 signaling, protein synthesis and markers of protein breakdown in human muscle. In study I, the influence of high intensity endurance exercise on subsequent resistance exercised induced mTORC1 signaling was examined. Despite robust activation of AMPK by the endurance exercise there was no inhibition of mTORC1 signaling or protein synthesis during recovery from resistance exercise. Study II utilized a similar set up, but with the difference that resistance exercise was performed with the triceps. The cycling exercise reduced the resistance exercise stimulated mTORC1 signaling immediately after the exercise, but during the recovery period mTORC1 signaling and protein synthesis was similar between trials. Concurrent exercise induced the mRNA expression of MuRF-1 and that of PGC-1α, the master regulator of mitochondrial biogenesis, in both studies, despite that the exercise modes in study II were separated between legs and arms. In study III, the effect of an EAA supplement with or without leucine, in the stimulation of mTORC1 signaling in connection with resistance exercise was examined. Intake of EAA robustly stimulated mTORC1 signaling after exercise, but this was only minor when leucine was excluded from the supplement. In study IV, subjects were supplied with leucine, BCAA, EAA or placebo in a randomized fashion during four sessions of resistance exercise. Leucine alone stimulated mTORC1 signaling after the exercise, but both the amplitude and extent of stimulation was substantially greater with EAA, an effect that was largely mediated by the BCAA as a group. In conclusion, endurance exercise prior to resistance exercise using the leg or arm muscles does not affect mTORC1 signaling or protein synthesis during the three hour recovery period from exercise, supporting compatibility between resistance- and endurance exercise induced signaling. Concurrent exercise increases the expression of the proteolytic marker MuRF-1 compared to resistance exercise only, which could indicate both and increased demand of cellular adaptive remodeling or a more direct detrimental proteolytic effect. Leucine is crucial among the EAA in the stimulation of mTORC1 signaling after exercise, its effect is however potentiated by intake of the remaining EAA. As a supplement a mixture of EAA must be regarded preferable, although the effect is largely mediated by the BCAA as a group.

The tumor suppressor TP53 is the most frequently altered gene in human cancers. The growth-promoting complex, mTORC1 plays a part of the oncogenic profile caused by dysfunctional p53. mTORC1 sits downstream of AMPK and other crucial tumor suppressors/oncogenes, PTEN, LKB1, and Akt. The antifolate pemetrexed was found by this laboratory to activate AMPK via the inhibition of the enzyme AICART in de novo purine synthesis. This work presents a mechanism of mTORC1 activation with p53 loss, as well as of mTORC1 inhibition by pemetrexed-induced AMPK. We have found that mTORC1 activity was substantially upregulated by the loss or mutation of p53. This activation involves the loss of TSC2 from lysosomal membranes, the site of mTORC1 activation by Rheb. We demonstrate that loss of lysosomal TSC2 increased the levels of lysosomal Rheb. Control of mTORC1 was restored by overexpression of TSC2, which correlated with decreased lysosomal Rheb. Surprisingly, pemetrexed-activated AMPK did not phosphorylate TSC2 because of an accumulation of nonfunctional p53, and a subsequent decrease in TSC2 mRNA. Accordingly, lysosomal TSC2 decreased, however, the levels of lysosomal Rheb decreased. Future studies will question whether the robust Raptor phosphorylation by pemetrexed is involved in this decrease in lysosomal Rheb. AMPK activation by pemetrexed also significantly increased the translocation of AMPK to the nucleus, and we will explore the function of this nuclear AMPK. Overall, these findings present a mechanism involved in the oncogenic signaling of mTORC1 with loss of p53 and offer insight into how pemetrexed reinstates control.

High-risk human papillomaviruses (HPVs) are associated with nearly all cases of cervical cancer and also contribute to other types of anogenital and oropharyngeal cancers. The high-risk HPV E6 oncoprotein contributes to malignant progression in part by the targeted degradation of the tumor suppressor p53. The activation of growth factor and nutrient sensing pathways including receptor protein tyrosine kinases (RPTKs) and mTORC1 may also support cellular transformation. Moreover, previous studies suggested that HPV16 E6 activates mTORC1. We are particularly interested in understanding the mechanisms by which HPV E6 activates mTORC1 and the function of mTORC1 activation in HPV infection. Here we show that high-risk HPV16 E6 activates mTORC1 signaling and increases cap dependent translation through an increase in S6K signaling and an increase in 4E-BP1 phosphorylation. Mechanistically we found that HPV16 E6 activates AKT under conditions of nutrient deprivation. The combined approach of phospho-tyrosine immunoprecipitations and Western blot identified HPV16 E6 mediated activation of a subset of receptor protein tyrosine kinases. HPV16 E6 activates RPTKs at least in part by increasing the internalization of phosphorylated and activated receptor species. The signaling adaptor protein Grb2 associates with HPV16 E6, and Grb2 knockdown abrogated HPV16 E6 mediated mTORC1 activation. We hypothesize that Grb2 may be important in relaying E6 mediated RPTK activation to downstream signaling cascades. In this dissertation we also evaluate mTORC1 signaling and cap dependent translation in cells expressing HPV16 E6 mutants and E6 proteins from other HPV types. Binding to p53 and the association with proteins that contain an LXXLL motif are important for HPV16 E6 mediated mTORC1 activation. An increase in mTORC1 activation and cap dependent translation is shared between high-and low-risk mucosal, but not cutaneous HPV E6 proteins. Association with proteins through their LXXLL binding motif is also important for low-risk mucosal HPV E6 activation of mTORC1 and cap dependent translation. Shared mucosal E6 activation of mTORC1 indicates that mTORC1 may be important for the viral lifecycle in mucosal epithelia. However, it does not rule out the possibility that together with other properties of high-risk HPV E6 proteins, mTORC1 activation may promote transformation.